Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
LB1908
Nanjing Legend Biotech Co.
Gastric Cancer
1 trial -
LB2102
Nanjing Legend Biotech Co.
Small Cell Lung Cancer Extensive Stage
1 trial -
LBR-101 IV
Teva Pharma GmbH
Bioavailability and Pharmacokinetics
1 trial -
LBT-3627
Biotech Pharmaceutical Co.,
Parkinson Disease
1 trial -
LCAR-AIO T cells
Nanjing Legend Biotech Co.
Relapsed/Refractory Autoimmune Diseases
1 trial -
LCAR-AIO T cells
Nanjing Legend Biotech Co.
Systemic Lupus Erythematosus (SLE)
1 trial -
LCAR-AIO T cells
Nanjing Legend Biotech Co.
Multiple Sclerosis (MS)
1 trial -
LCAR-AIO cells product
Nanjing Legend Biotech Co.
B-cell Lymphoma Recurrent
1 trial -
LCAR-AMDR Cells Product
Nanjing Legend Biotech Co.
Acute Myeloid Leukemia
1 trial -
LCAR-B4822M CAR-T Cell Immunotherapy
Nanjing Legend Biotech Co.
Refractory or Relapsed Multiple Myeloma
1 trial -
LCAR-BCDR cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
LCAR-BCX cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
LCAR-C182A cells
Nanjing Legend Biotech Co.
Gastric Cancer
1 trial -
LCAR-C18S cells
Nanjing Legend Biotech Co.
Solid Tumors, Adult
1 trial -
LCAR-G08 cells
Nanjing Legend Biotech Co.
Advanced Gastrointestinal Tumors
1 trial -
LCAR-HL30 cells
Nanjing Legend Biotech Co.
Hodgkin's Lymphoma
1 trial -
LCAR-M23 cells
Nanjing Legend Biotech Co.
Epithelial Ovarian Cancer
1 trial -
LN-144
Iovance Biotherapeutics B.V.
Stage IIIB Melanoma
1 trial -
LN-145/LN-144
Iovance Biotherapeutics B.V.
Soft Tissue Sarcoma
1 trial -
LOR-253 HCl
Aptose Biosciences
Advanced or Metastatic Solid Tumours
1 trial -
LTI-03
Shanghai Reinovax Biologics Co.,LTD
Idiopathic Pulmonary Fibrosis
1 trial -
LUCAR-20S CAR-T cells
Nanjing Legend Biotech Co.
Diffuse Large B Cell Lymphoma
1 trial -
LUCAR-20SP cells
Nanjing Legend Biotech Co.
Relapsed B-cell Non-Hodgkin Lymphoma
1 trial -
LUCAR-B68 cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources